SCHEMBL394576

SCHEMBL394576

CC(=O)CC(=O)c1ccc(Br)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.59
HAO1 Q9UJM8 1/20 0.56
HDAC1 Q13547 4/20 0.55
HDAC8 Q9BY41 3/20 0.55
HDAC3 O15379 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC4 P56524 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55
OGG1 O15527 1/20 0.52
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 2/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17973414 0.94 HAO1 (0.66) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL2003577 0.89 KMT2A (0.52) GSK3BHAO1CES1ALDH1A1KMT2A
SCHEMBL1305020 0.86 GSK3B (0.70) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL6286372 0.81 GSK3B (0.57) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL6351346 0.80 HSD17B3 (0.57) ALDH1A1POLBCA1CA2HPGD
SCHEMBL9754092 0.80 TSHR (0.55) CES1ALDH1A1KMT2AMEN1CA1
SCHEMBL3035986 0.80 NPC1 (0.67) GSK3BHDAC1HDAC6CES2CES1
SCHEMBL2635792 0.80 HAO1 (0.63) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL21202169 0.79 GSK3B (0.55) GSK3BHAO1HDAC1HDAC8HDAC3
SCHEMBL11827259 0.79 GSK3B (0.55) GSK3BHAO1HDAC1HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119609119-B Modification method of rare earth superfine nanowire, fluorescent ink, preparation method and application 稀致远达(天津)新材料有限公司 2025-06-24 CN claimed
CN-119609119-A Modification method of rare earth superfine nanowire, fluorescent ink, preparation method and application 稀致远达(天津)新材料有限公司 2025-03-14 CN claimed
US-7067702-B2 Process for preparing vinyl substituted beta-diketones THE JOHNS HOPKINS UNIVERSITY (US) 2006-06-27 US claimed
US-20060069288-A1 Process for preparing vinyl substituted beta-diketones THE JOHNS HOPKINS UNIVERSITY 2006-03-30 US claimed
US-20250263394-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF INVENTISBIO LLC 2025-08-21 US disclosed
CN-119609119-B Modification method of rare earth superfine nanowire, fluorescent ink, preparation method and application 稀致远达(天津)新材料有限公司 2025-06-24 CN disclosed
CN-119609119-A Modification method of rare earth superfine nanowire, fluorescent ink, preparation method and application 稀致远达(天津)新材料有限公司 2025-03-14 CN disclosed
CN-119095846-A Compounds, methods of preparation and uses thereof 益方生物科技(上海)股份有限公司 2024-12-06 CN disclosed
CN-118271261-A Dicarbonyl compound containing cyclobutane segment and synthesis method thereof 中国科学技术大学 2024-07-02 CN disclosed
EP-4340056-A1 POSITIVE ELECTRODE MIXTURE, POSITIVE ELECTRODE AND SECONDARY BATTERY Daikin Industries, Ltd. (JP) 2024-03-20 EP disclosed
US-20240088381-A1 POSITIVE ELECTRODE MIXTURE, POSITIVE ELECTRODE AND SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2024-03-14 US disclosed
EP-4336584-A1 POSITIVE ELECTRODE MIXTURE, POSITIVE ELECTRODE AND SECONDARY BATTERY Daikin Industries, Ltd. (JP) 2024-03-13 EP disclosed
EP-1416936-A1 THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS Cancer Research Technology Limited (GB) 2004-05-12 EP disclosed
WO-2003015790-A1 THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-02-27 WO disclosed
EP-0210284-B1 1,3-DITHIOL-2-YLIDENE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1992-08-19 EP disclosed
EP-0234480-A2 1, 3-diketone derivatives and their use NIHON NOHYAKU CO., LTD. (JP) 1987-09-02 EP disclosed
US-4668799-A Anti-hepatitis and anti-cirrhotic 1,3-dithiol-2-ylidene derivatives, and pharmaceutical compositions therefor BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-05-26 US disclosed
EP-0210284-A1 1,3-Dithiol-2-ylidene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-02-04 EP disclosed
EP-0168037-A2 1-6-Naphthyridin-2(1H)-ones useful as cardiotonics STERLING DRUG INC. (US) 1986-01-15 EP disclosed
US-4560691-A 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation STERLING DRUG INC. (US) 1985-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263394-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF PIK3CD, PIK3CA, PIK3C2B GSK3B 127/4885HAO1 4598/4885HDAC1 451/4885
US-20060069288-A1 Process for preparing vinyl substituted beta-diketones VRK1, VRK2, DEK GSK3B 528/4885HAO1 835/4885HDAC1 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.